115 Publications (Page 1 of 5)
2021
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2Clark, Joseph I⋅Curti, Brendan⋅Davis, Elizabeth J⋅Kaufman, Howard⋅Amin, Asim⋅Logan, Theodore F⋅Hauke, Ralph⋅Miletello, Gerald P⋅Vaishampayan, Ulka⋅Johnson, Douglas B⋅White, Richard L⋅Wiernik, Peter H and Dutcher, Janice PJournal of Investigative Medicine, vol. 69, (no. 4), pp. 888-892, Apr 2021.
| Journal Article
2020
Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003Dudek, Arkadiusz Z⋅Dudek, A.Z.⋅Dudek, Arkadiusz Z⋅Liu, Li C⋅Liu, L.C.⋅Liu, Li C⋅Gupta, Shilpa⋅Gupta, Shilpa⋅Gupta, S.⋅Logan, Theodore F⋅Logan, T.F.⋅Logan, Theodore F⋅Singer, Eric A⋅Singer, Eric A⋅Singer, E.A.⋅Joshi, M.⋅Joshi, Monika⋅Joshi, Monika⋅Zakharia, Y.N.⋅Zakharia, Yousef N⋅Zakharia, Yousef N⋅Lang, Joshua M⋅Lang, J.M.⋅Lang, Joshua M⋅Schwarz, James K⋅Schwarz, James K⋅Schwarz, J.K.⋅Al-Janadi, A.⋅Al-Janadi, Anas⋅Al-Janadi, Anas⋅Alva, Ajjai S⋅Alva, Ajjai S and Alva, A.S.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, (no. 11), pp. 1145, 2020-Apr-10.
| Journal Article
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphomaTimmerman, John⋅Timmerman, John⋅Herbaux, Charles⋅Herbaux, Charles⋅Ribrag, Vincent⋅Ribrag, Vincent⋅Zelenetz, Andrew D⋅Zelenetz, Andrew D⋅Houot, Roch⋅Houot, Roch⋅Neelapu, Sattva S⋅Neelapu, Sattva S⋅Logan, Theodore⋅Logan, Theodore⋅Lossos, Izidore S⋅Lossos, Izidore S⋅Urba, Walter⋅Urba, Walter⋅Salles, Gilles⋅Salles, Gilles⋅Ramchandren, Radhakrishnan⋅Ramchandren, Radhakrishnan⋅Jacobson, Caron⋅Jacobson, Caron⋅Godwin, John⋅Godwin, John⋅Carpio, Cecilia⋅Carpio, Cecilia⋅Lathers, Deanne⋅Lathers, Deanne⋅Liu, Yali⋅Liu, Yali⋅Neely, Jaclyn⋅Neely, Jaclyn⋅Suryawanshi, Satyendra⋅Suryawanshi, Satyendra⋅Koguchi, Yoshinobu⋅Koguchi, Yoshinobu⋅Levy, Ronald and Levy, RonaldAmerican Journal of Hematology, vol. 95, (no. 5), pp. 520, May 2020.
| Journal Article
2019
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinomaVoss, Martin H⋅Voss, Martin H⋅Bhatt, Rupal S⋅Bhatt, Rupal S⋅Vogelzang, Nicholas J⋅Vogelzang, Nicholas J⋅Fishman, Mayer⋅Fishman, Mayer⋅Alter, Robert S⋅Alter, Robert S⋅Rini, Brian I⋅Rini, Brian I⋅Beck, J T⋅Beck, J T⋅Joshi, Monika⋅Joshi, Monika⋅Hauke, Ralph⋅Hauke, Ralph⋅Atkins, Michael B⋅Atkins, Michael B⋅Burgess, Earle⋅Burgess, Earle⋅Logan, Theodore F⋅Logan, Theodore F⋅Shaffer, David⋅Shaffer, David⋅Parikh, Rahul⋅Parikh, Rahul⋅Zhang, Xiaosha⋅Zhang, Xiaosha⋅Glasser, Chad⋅Glasser, Chad⋅Sherman, Matthew L⋅Sherman, Matthew L⋅Plimack, Elizabeth R and Plimack, Elizabeth RCancer, vol. 125, (no. 14), pp. 2400-2408, Jul 2019.
| Journal Article
Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patientsPili, Roberto⋅Pili, Roberto⋅Pili, Roberto⋅Pili, Roberto⋅Pili, Roberto⋅Pili, Roberto⋅Quinn, David I⋅Quinn, David I⋅Quinn, David I⋅Quinn, David I⋅Quinn, David I⋅Quinn, David I⋅Albany, Costantine⋅Albany, Costantine⋅Albany, Costantine⋅Albany, Costantine⋅Albany, Costantine⋅Albany, Costantine⋅Adra, Nabil⋅Adra, Nabil⋅Adra, Nabil⋅Adra, Nabil⋅Adra, Nabil⋅Adra, Nabil⋅Logan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F⋅Greenspan, Andrew⋅Greenspan, Andrew⋅Greenspan, Andrew⋅Greenspan, Andrew⋅Greenspan, Andrew⋅Greenspan, Andrew⋅Budka, Justin⋅Budka, Justin⋅Budka, Justin⋅Budka, Justin⋅Budka, Justin⋅Budka, Justin⋅Damayanti, Nur⋅Damayanti, Nur⋅Damayanti, Nur⋅Damayanti, Nur⋅Damayanti, Nur⋅Green, Mark A⋅Green, Mark A⋅Green, Mark A⋅Green, Mark A⋅Green, Mark A⋅Green, Mark A⋅Fletcher, James W⋅Fletcher, James W⋅Fletcher, James W⋅Fletcher, James W⋅Fletcher, James W⋅Fletcher, James W⋅Tann, Mark⋅Tann, Mark⋅Tann, Mark⋅Tann, Mark⋅Tann, Mark⋅Tann, Mark⋅Edwards, Sara I⋅Edwards, Sara I⋅Edwards, Sara I⋅Edwards, Sara I⋅Edwards, Sara I⋅Edwards, Sara I⋅Burney, Heather⋅Burney, Heather⋅Burney, Heather⋅Burney, Heather⋅Burney, Heather⋅Burney, Heather⋅Liu, Hao⋅Liu, Hao⋅Liu, Hao⋅Liu, Hao⋅Liu, Hao⋅Liu, Hao⋅Hahn, Noah M⋅Hahn, Noah M⋅Hahn, Noah M⋅Hahn, Noah M⋅Hahn, Noah M and Hahn, Noah MJournal of Clinical Oncology, vol. 37, (no. 15_suppl), pp. 2572, 2019-05-20.
| Journal Article
2018
A Clinically Suitable Approach to Whole-Body Imaging for Quantification of Regional Perfusion: Validation of Positron Emission Tomography (PET) with 62Cu-ETS and Image-based Tracer Kinetic ModelingCheng, Monica⋅Cheng, Monica⋅Smith, Nathaniel J⋅Smith, Nathaniel J⋅Territo, Wendy L⋅Territo, Wendy L⋅Mathias, Carla J⋅Mathias, Carla J⋅Fletcher, James W⋅Fletcher, James W⋅Logan, Theodore F⋅Logan, Theodore F⋅Green, Mark A⋅Green, Mark A⋅Hutchins, Gary D and Hutchins, Gary DProceedings of IMPRS, vol. 1, (no. 1), 2018-12-07.
| Journal Article
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.Clark, Joseph I⋅Singh, Jatinder⋅Ernstoff, Marc S⋅Lao, Christopher D⋅Flaherty, Lawrence E⋅Logan, Theodore F⋅Curti, Brendan⋅Agarwala, Sanjiv S⋅Taback, Bret⋅Cranmer, Lee⋅Lutzky, Jose⋅Luna, Theresa L⋅Aung, Sandra and Lawson, David HJournal for immunotherapy of cancer, vol. 6, (no. 1), pp. 76, July 27, 2018.
| Journal Article
Clinical features and survival outcomes in a prospective spontaneous regression (SR) protocol of renal cell carcinoma (RCC) and melanoma (M) patientsGbolahan, Olumide B⋅Gbolahan, Olumide B⋅Gbolahan, Olumide B⋅Hashemi-Sadraei, Neda⋅Hashemi-Sadraei, Neda⋅Hashemi-Sadraei, Neda⋅Conteh, Abass⋅Conteh, Abass⋅Conteh, Abass⋅Kaimakliotis, Hristos Z⋅Kaimakliotis, Hristos Z⋅Kaimakliotis, Hristos Z⋅Storkus, Walter⋅Storkus, Walter⋅Storkus, Walter⋅Pili, Roberto⋅Pili, Roberto⋅Pili, Roberto⋅Logan, Theodore F⋅Logan, Theodore F and Logan, Theodore FJournal of Clinical Oncology, vol. 36, (no. 15_suppl), pp. e16585, 2018-05-20.
| Journal Article
NCI 8628: a randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma.Tarhini, Ahmad A⋅Tarhini, Ahmad A⋅Tarhini, Ahmad A⋅Tarhini, Ahmad A⋅Tarhini, Ahmad A⋅Tarhini, Ahmad A⋅Frankel, Paul⋅Frankel, Paul⋅Frankel, Paul⋅Frankel, Paul⋅Frankel, Paul⋅Frankel, Paul⋅Ruel, Christopher⋅Ruel, Christopher⋅Ruel, Christopher⋅Ruel, Christopher⋅Ruel, Christopher⋅Ruel, Christopher⋅Ernstoff, Marc S⋅Ernstoff, Marc S⋅Ernstoff, Marc S⋅Ernstoff, Marc S⋅Ernstoff, Marc S⋅Ernstoff, Marc S⋅Kuzel, Timothy M⋅Kuzel, Timothy M⋅Kuzel, Timothy M⋅Kuzel, Timothy M⋅Kuzel, Timothy M⋅Kuzel, Timothy M⋅Logan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F⋅Khushalani, Nikhil I⋅Khushalani, Nikhil I⋅Khushalani, Nikhil I⋅Khushalani, Nikhil I⋅Khushalani, Nikhil I⋅Khushalani, Nikhil I⋅Tawbi, Hussein A⋅Tawbi, Hussein A⋅Tawbi, Hussein A⋅Tawbi, Hussein A⋅Tawbi, Hussein A⋅Tawbi, Hussein A⋅Margolin, Kim A⋅Margolin, Kim A⋅Margolin, Kim A⋅Margolin, Kim A⋅Margolin, Kim A⋅Margolin, Kim A⋅Awasthi, Sanjay⋅Awasthi, Sanjay⋅Awasthi, Sanjay⋅Awasthi, Sanjay⋅Awasthi, Sanjay⋅Awasthi, Sanjay⋅Butterfield, Lisa H⋅Butterfield, Lisa H⋅Butterfield, Lisa H⋅Butterfield, Lisa H⋅Butterfield, Lisa H⋅Butterfield, Lisa H⋅McDermott, David⋅McDermott, David⋅Mc Dermott, David⋅McDermott, David⋅Mc Dermott, David⋅McDermott, David⋅Chen, Alice⋅Chen, Alice⋅Chen, Alice⋅Chen, Alice⋅Chen, Alice⋅Chen, Alice⋅Lara, Primo N⋅Lara, Primo N⋅Lara, Primo N⋅Lara, Primo N⋅Lara, Primo N⋅Lara, Primo N⋅Kirkwood, John M⋅Kirkwood, John M⋅Kirkwood, John M⋅Kirkwood, John M⋅Kirkwood, John M and Kirkwood, John MCancer, October 10, 2018.
| Journal Article
PET/CT assessment of tumor perfusion (TP) in metastatic renal cell cancer (RCC) patients (pts) on sunitinib (S) using 62Cu-ETSLogan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F⋅Fletcher, James W⋅Fletcher, James W⋅Fletcher, James W⋅Fletcher, James W⋅Green, Mark A⋅Green, Mark A⋅Green, Mark A⋅Green, Mark A⋅Eitel, Jacob Aaron⋅Eitel, Jacob Aaron⋅Eitel, Jacob Aaron⋅Eitel, Jacob Aaron⋅Althouse, Sandra K⋅Althouse, Sandra K⋅Althouse, Sandra K⋅Althouse, Sandra K⋅Perkins, Susan M⋅Perkins, Susan M⋅Perkins, Susan M⋅Perkins, Susan M⋅Hutchins, Gary⋅Hutchins, Gary⋅Hutchins, Gary and Hutchins, GaryJournal of Clinical Oncology, vol. 36, (no. 15_suppl), pp. e16567, 2018-05-20.
| Journal Article
Prognostic role of BRAF mutation in malignant cutaneous melanomaSehdev, Amikar⋅Sehdev, Amikar⋅Sehdev, Amikar⋅Sehdev, Amikar⋅Sehdev, Amikar⋅Hayden, Ross⋅Hayden, Ross⋅Hayden, Ross⋅Hayden, Ross⋅Hayden, Ross⋅Kuhar, Mathew Joseph⋅Kuhar, Mathew Joseph⋅Kuhar, Mathew Joseph⋅Kuhar, Mathew Joseph⋅Kuhar, Mathew Joseph⋅Cheng, Liang⋅Cheng, Liang⋅Cheng, Liang⋅Cheng, Liang⋅Cheng, Liang⋅Warren, Simon John⋅Warren, Simon John⋅Warren, Simon John⋅Warren, Simon John⋅Warren, Simon John⋅Mark, Lawrence Aaron⋅Mark, Lawrence Aaron⋅Mark, Lawrence Aaron⋅Mark, Lawrence Aaron⋅Mark, Lawrence Aaron⋅Wooden, William Arthur⋅Wooden, William Arthur⋅Wooden, William Arthur⋅Wooden, William Arthur⋅Wooden, William Arthur⋅Schwartzentruber, Douglas Jay⋅Schwartzentruber, Douglas Jay⋅Schwartzentruber, Douglas Jay⋅Schwartzentruber, Douglas Jay⋅Schwartzentruber, Douglas Jay⋅Logan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F and Logan, Theodore FJournal of Clinical Oncology, vol. 36, (no. 15_suppl), pp. e21599, 2018-05-20.
| Journal Article
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable MelanomaChesney, Jason⋅Chesney, Jason⋅Chesney, Jason⋅Chesney, Jason⋅Chesney, Jason⋅Puzanov, Igor⋅Puzanov, Igor⋅Puzanov, Igor⋅Puzanov, Igor⋅Puzanov, Igor⋅Collichio, Frances⋅Collichio, Frances⋅Collichio, Frances⋅Collichio, Frances⋅Collichio, Frances⋅Singh, Parminder⋅Singh, Parminder⋅Singh, Parminder⋅Singh, Parminder⋅Singh, Parminder⋅Milhem, Mohammed M⋅Milhem, Mohammed M⋅Milhem, Mohammed M⋅Milhem, Mohammed M⋅Milhem, Mohammed M⋅Glaspy, John⋅Glaspy, John⋅Glaspy, John⋅Glaspy, John⋅Glaspy, John⋅Hamid, Omid⋅Hamid, Omid⋅Hamid, Omid⋅Hamid, Omid⋅Hamid, Omid⋅Ross, Merrick⋅Ross, Merrick⋅Ross, Merrick⋅Ross, Merrick⋅Ross, Merrick⋅Friedlander, Philip⋅Friedlander, Philip⋅Friedlander, Philip⋅Friedlander, Philip⋅Friedlander, Philip⋅Garbe, Claus⋅Garbe, Claus⋅Garbe, Claus⋅Garbe, Claus⋅Garbe, Claus⋅Logan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F⋅Hauschild, Axel⋅Hauschild, Axel⋅Hauschild, Axel⋅Hauschild, Axel⋅Hauschild, Axel⋅Lebbé, Celeste⋅Lebbé, Celeste⋅Lebbé, Celeste⋅Lebbé, Celeste⋅Lebbé, Celeste⋅Chen, Lisa⋅Chen, Lisa⋅Chen, Lisa⋅Chen, Lisa⋅Chen, Lisa⋅Kim, Jenny J⋅Kim, Jenny J⋅Kim, Jenny J⋅Kim, Jenny J⋅Kim, Jenny J⋅Gansert, Jennifer⋅Gansert, Jennifer⋅Gansert, Jennifer⋅Gansert, Jennifer⋅Gansert, Jennifer⋅Andtbacka, Robert H I⋅Andtbacka, Robert H I⋅Andtbacka, Robert H I⋅Andtbacka, Robert H I⋅Andtbacka, Robert H I⋅Kaufman, Howard L⋅Kaufman, Howard L⋅Kaufman, Howard L⋅Kaufman, Howard L and Kaufman, Howard LJournal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 36, (no. 17), pp. 1667, 2018-06-10.
| Journal Article
Safety and activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma: A cytokine working group phase II studyAppleman, Leonard Joseph⋅Appleman, Leonard Joseph⋅Normolle, Daniel Paul⋅Normolle, Daniel Paul⋅Logan, Theodore F⋅Logan, Theodore F.⋅Monk, Paul⋅Monk, Paul⋅Olencki, Thomas⋅Olencki, Thomas⋅McDermott, David F⋅McDermott, David F.⋅Ernstoff, Marc S.⋅Ernstoff, Marc S⋅Maranchie, Jodi Kathleen⋅Maranchie, Jodi Kathleen⋅Parikh, Rahul Atul⋅Parikh, Rahul Atul⋅Friedland, David⋅Friedland, David⋅Zeh, Herbert⋅Zeh, Herbert⋅Liang, Xiaoyan⋅Liang, Xiaoyan⋅Butterfield, Lisa Helene⋅Butterfield, Lisa Helene⋅Lotze, Michael T. and Lotze, Michael TJournal of Clinical Oncology, vol. 36, (no. 15_suppl), pp. 4573, 2018-05-20.
| Journal Article
Sustained Exceptional Response to Poly (ADP-Ribose) Polymerase Inhibition Plus Temozolomide in Metastatic Melanoma With DNA Repair DeficiencyKiel, Patrick J⋅Kiel, Patrick J⋅Kiel, Patrick J⋅Radovich, Milan⋅Radovich, Milan⋅Radovich, Milan⋅Schneider, Bryan P⋅Schneider, Bryan P⋅Schneider, Bryan P⋅Logan, Theodore F⋅Logan, Theodore F and Logan, Theodore FJCO Precision Oncology, (no. 2), pp. 7, 2018-11-00.
| Journal Article
Targeting autophagy and immunotherapy with hydroxychloroquine and interleukin 2 in patients with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group studyAppleman, Leonard Joseph⋅Appleman, Leonard Joseph⋅Logan, Theodore F⋅Logan, Theodore F.⋅Normolle, Daniel Paul⋅Normolle, Daniel Paul⋅Ernstoff, Marc S⋅Ernstoff, Marc S.⋅Parikh, Rahul Atul⋅Parikh, Rahul Atul⋅McDermott, David F.⋅McDermott, David F⋅Monk, Paul⋅Monk, Paul⋅Olencki, Thomas⋅Olencki, Thomas⋅Friedland, David⋅Friedland, David⋅Maranchie, Jodi Kathleen⋅Maranchie, Jodi Kathleen⋅Butterfield, Lisa Helene⋅Butterfield, Lisa Helene⋅Liang, Xiaoyan⋅Liang, Xiaoyan⋅Lotze, Michael T. and Lotze, Michael TJournal of Clinical Oncology, vol. 36, (no. 5_suppl), pp. 106, 2018-02-10.
| Journal Article
2017
Abstract 3827: NCI 8628 - A randomized phase II study of Ziv-aflibercept (Z) and high dose Interleukin-2 (IL-2) or IL-2 alone for inoperable stage III or IV melanomaTarhini, Ahmad A⋅Tarhini, Ahmad A⋅Frankel, Paul H⋅Frankel, Paul H⋅Ruel, Christopher⋅Ruel, Christopher⋅Ernstoff, Marc S⋅Ernstoff, Marc S⋅Kuzel, Timothy M⋅Kuzel, Timothy M⋅Logan, Theodore F⋅Logan, Theodore F⋅Khushalani, Nikhil I⋅Khushalani, Nikhil I⋅Tawbi, Hussein A⋅Tawbi, Hussein A⋅Margolin, Kim A⋅Margolin, Kim A⋅Awasthi, Sanjay⋅Awasthi, Sanjay⋅McDermott, David F⋅McDermott, David F⋅Chen, Alice⋅Chen, Alice⋅Lara, Primo N⋅Lara, Primo N⋅Kirkwood, John M and Kirkwood, John MCancer Research, vol. 77, (no. 13 Supplement), pp. 3827, 2017-07-01.
| Journal Article
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM SM registryCurti, Brendan⋅Curti, Brendan⋅Daniels, Gregory A⋅Daniels, Gregory A⋅McDermott, David F⋅McDermott, David F⋅Clark, Joseph I⋅Clark, Joseph I⋅Kaufman, Howard L⋅Kaufman, Howard L⋅Logan, Theodore F⋅Logan, Theodore F⋅Singh, Jatinder⋅Singh, Jatinder⋅Kaur, Meenu⋅Kaur, Meenu⋅Luna, Theresa L⋅Luna, Theresa L⋅Gregory, Nancy⋅Gregory, Nancy⋅Morse, Michael A⋅Morse, Michael A⋅Wong, Michael K K⋅Wong, Michael K K⋅Dutcher, Janice P and Dutcher, Janice PJournal for immunotherapy of cancer, vol. 5, (no. 1), pp. 102, 2017-Dec-19.
| Journal Article
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registryCurti, Brendan⋅Curti, Brendan⋅Curti, Brendan⋅Curti, Brendan⋅Daniels, Gregory A⋅Daniels, Gregory A⋅Daniels, Gregory A⋅Daniels, Gregory⋅McDermott, David F⋅Mc Dermott, David F⋅McDermott, David F⋅McDermott, David⋅Clark, Joseph I⋅Clark, Joseph⋅Clark, Joseph I⋅Clark, Joseph I⋅Kaufman, Howard⋅Kaufman, Howard L⋅Kaufman, Howard L⋅Kaufman, Howard L⋅Logan, Theodore⋅Logan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F⋅Singh, Jatinder⋅Singh, Jatinder⋅Singh, Jatinder⋅Singh, Jatinder⋅Kaur, Meenu⋅Kaur, Meenu⋅Kaur, Meenu⋅Kaur, Meenu⋅Luna, Theresa L⋅Luna, Theresa L⋅Luna, Theresa L⋅Luna, Theresa⋅Gregory, Nancy⋅Gregory, Nancy⋅Gregory, Nancy⋅Gregory, Nancy⋅Morse, Michael A⋅Morse, Michael A⋅Morse, Michael⋅Morse, Michael A⋅Wong, Michael K. K⋅Wong, Michael K. K⋅Wong, Michael⋅Wong, Michael K K⋅Dutcher, Janice P⋅Dutcher, Janice P⋅Dutcher, Janice P and Dutcher, JaniceJournal for ImmunoTherapy of Cancer, vol. 5, (no. 1), pp. 102, 2017-12-00.
| Journal Article
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal AntibodySegal, Neil H⋅Segal, Neil H⋅Segal, Neil H⋅Segal, Neil H⋅Segal, Neil H⋅Logan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F⋅Hodi, F Stephen⋅Stephen, Hodi F⋅Stephen, Hodi F⋅Stephen, Hodi F⋅Hodi, F Stephen⋅McDermott, David⋅Mc Dermott, David⋅Mc Dermott, David⋅McDermott, David⋅McDermott, David⋅Melero, Ignacio⋅Melero, Ignacio⋅Hamid, Omid⋅Hamid, Omid⋅Schmidt, Henrik⋅Schmidt, Henrik⋅Schmidt, Henrik⋅Schmidt, Henrik⋅Schmidt, Henrik⋅Robert, Caroline⋅Robert, Caroline⋅Robert, Caroline⋅Robert, Caroline⋅Robert, Caroline⋅Chiarion-Sileni, Vanna⋅Chiarion-Sileni, Vanna⋅Ascierto, Paolo A⋅Ascierto, Paolo A⋅Ascierto, Paolo A⋅Ascierto, Paolo A⋅Ascierto, Paolo A⋅Maio, Michele⋅Maio, Michele⋅Maio, Michele⋅Maio, Michele⋅Maio, Michele⋅Urba, Walter J⋅Urba, Walter J⋅Urba, Walter J⋅Urba, Walter J⋅Urba, Walter J⋅Gangadhar, Tara C⋅Gangadhar, Tara C⋅Gangadhar, Tara C⋅Gangadhar, Tara C⋅Gangadhar, Tara C⋅Suryawanshi, Satyendra⋅Suryawanshi, Satyendra⋅Neely, Jaclyn⋅Neely, Jaclyn⋅Jure-Kunkel, Maria⋅Jure-Kunkel, Maria⋅Jure-Kunkel, Maria⋅Jure-Kunkel, Maria⋅Jure-Kunkel, Maria⋅Krishnan, Suba⋅Krishnan, Suba⋅Holbrook, Kohrt⋅Kohrt, Holbrook⋅Holbrook, Kohrt⋅Kohrt, Holbrook⋅Holbrook, Kohrt⋅Sznol, Mario⋅Sznol, Mario⋅Levy, Ronald⋅Levy, Ronald⋅Levy, Ronald⋅Levy, Ronald and Levy, RonaldClinical cancer research : an official journal of the American Association for Cancer Research, vol. 23, (no. 8), pp. 1936, 2017-04-15.
| Journal Article
Safety and preliminary activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma (mRCC): A cytokine working group studyAppleman, Leonard Joseph⋅Appleman, Leonard Joseph⋅Logan, Theodore F⋅Logan, Theodore F.⋅Normolle, Daniel Paul⋅Normolle, Daniel Paul⋅Ernstoff, Marc S⋅Ernstoff, Marc S.⋅Parikh, Rahul Atul⋅Parikh, Rahul Atul⋅McDermott, David F⋅McDermott, David F.⋅Monk, Paul⋅Monk, Paul⋅Olencki, Thomas⋅Olencki, Thomas⋅Friedland, David⋅Friedland, David⋅Maranchie, Jodi Kathleen⋅Maranchie, Jodi Kathleen⋅Lotze, Michael T. and Lotze, Michael TJournal of Clinical Oncology, vol. 35, (no. 6_suppl), pp. 440, 2017-02-20.
| Journal Article
2016
A phase I/Ib, open-label, dose-finding study to evaluate safety, pharmacodynamics, and efficacy of pembrolizumab (MK-3475) in combination with vorinostat in patients with advanced renal or urothelial cell carcinomaPili, Roberto⋅Pili, Roberto⋅Quinn, David⋅Quinn, David⋅Hahn, Noah M⋅Hahn, Noah M⋅Albany, Costantine⋅Albany, Costantine⋅Logan, Theodore F⋅Logan, Theodore F⋅Drake, Charles G and Drake, Charles GJournal of Clinical Oncology, vol. 34, (no. 15_suppl), pp. TPS4581, 2016-05-20.
| Journal Article
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinomaAlva, Ajjai⋅Alva, Ajjai⋅Alva, Ajjai⋅Alva, Ajjai⋅Daniels, Gregory⋅Daniels, Gregory A⋅Daniels, Gregory A⋅Daniels, Gregory⋅Wong, Michael K⋅Wong, Michael K. K⋅Wong, Michael⋅Wong, Michael⋅Kaufman, Howard L⋅Kaufman, Howard⋅Kaufman, Howard⋅Kaufman, Howard L⋅Morse, Michael A⋅Morse, Michael⋅Morse, Michael A⋅Morse, Michael⋅Mcdermott, David⋅McDermott, David⋅Mc Dermott, David F⋅McDermott, David F⋅Mcdermott, David F⋅Clark, Joseph I⋅Clark, Joseph⋅Clark, Joseph I⋅Clark, Joseph⋅Agarwala, Sanjiv S⋅Agarwala, Sanjiv⋅Agarwala, Sanjiv⋅Agarwala, Sanjiv S⋅Miletello, Gerald⋅Miletello, Gerald⋅Miletello, Gerald⋅Miletello, Gerald⋅Logan, Theodore⋅Logan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore⋅Hauke, Ralph J⋅Hauke, Ralph⋅Hauke, Ralph⋅Hauke, Ralph J⋅Curti, Brendan⋅Curti, Brendan⋅Curti, Brendan⋅Curti, Brendan⋅Kirkwood, John⋅Kirkwood, John M⋅Kirkwood, John⋅Kirkwood, John M⋅Gonzalez, Rene⋅Gonzalez, Rene⋅Gonzalez, Rene⋅Gonzalez, Rene⋅Amin, Asim⋅Amin, Asim⋅Amin, Asim⋅Amin, Asim⋅Fishman, Mayer⋅Fishman, Mayer⋅Fishman, Mayer⋅Fishman, Mayer⋅Agarwal, Neeraj⋅Agarwal, Neeraj⋅Agarwal, Neeraj⋅Agarwal, Neeraj⋅Lowder, James⋅Lowder, James⋅Lowder, James N⋅Lowder, James N⋅Hua, Hong⋅Hua, Hong⋅Hua, Hong⋅Hua, Hong⋅Aung, Sandra⋅Aung, Sandra⋅Aung, Sandra⋅Aung, Sandra⋅Dutcher, Janice⋅Dutcher, Janice P⋅Dutcher, Janice P and Dutcher, JaniceCancer Immunology, Immunotherapy, vol. 65, (no. 12), pp. 1533-1544, Dec 2016.
| Journal Article
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.Armstrong, Andrew J⋅Armstrong, Andrew J⋅Armstrong, Andrew J⋅Halabi, Susan⋅Halabi, Susan⋅Halabi, Susan⋅Eisen, Tim⋅Eisen, Tim⋅Eisen, Tim⋅Broderick, Samuel⋅Broderick, Samuel⋅Broderick, Samuel⋅Stadler, Walter M⋅Stadler, Walter M⋅Stadler, Walter M⋅Jones, Robert J⋅Jones, Robert J⋅Jones, Robert J⋅Garcia, Jorge A⋅Garcia, Jorge A⋅Garcia, Jorge A⋅Vaishampayan, Ulka N⋅Vaishampayan, Ulka N⋅Vaishampayan, Ulka N⋅Picus, Joel⋅Picus, Joel⋅Picus, Joel⋅Hawkins, Robert E⋅Hawkins, Robert E⋅Hawkins, Robert E⋅Hainsworth, John D⋅Hainsworth, John D⋅Hainsworth, John D⋅Kollmannsberger, Christian K⋅Kollmannsberger, Christian K⋅Kollmannsberger, Christian K⋅Logan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F⋅Puzanov, Igor⋅Puzanov, Igor⋅Puzanov, Igor⋅Pickering, Lisa M⋅Pickering, Lisa M⋅Pickering, Lisa M⋅Ryan, Christopher W⋅Ryan, Christopher W⋅Ryan, Christopher W⋅Protheroe, Andrew⋅Protheroe, Andrew⋅Protheroe, Andrew⋅Lusk, Christine M⋅Lusk, Christine M⋅Lusk, Christine M⋅Oberg, Sadie⋅Oberg, Sadie⋅Oberg, Sadie⋅George, Daniel J⋅George, Daniel J and George, Daniel JThe Lancet. Oncology, vol. 17, (no. 3), pp. 378-388, March 2016.
| Journal Article
Results From an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.Segal, Neil H⋅Logan, Theodore F⋅Hodi, F Stephen⋅Mc Dermott, David F⋅Melero, Ignacio⋅Hamid, Omid⋅Schmidt, Henrik⋅Robert, Caroline⋅Chiarion-Sileni, Vanna⋅Ascierto, Paolo A⋅Maio, Michele⋅Urba, Walter J⋅Gangadhar, Tara C⋅Suryawanshi, Satyendra⋅Neely, Jaclyn⋅Jure-Kunkel, Maria⋅Krishnan, Suba⋅Kohrt, Holbrook E⋅Sznol, Mario and Levy, RonaldClinical cancer research : an official journal of the American Association for Cancer Research, October 18, 2016.
| Journal Article
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.Weber, Jeffrey S⋅Weber, Jeffrey S⋅Weber, Jeffrey S⋅Gibney, Geoff⋅Gibney, Geoff⋅Gibney, Geoff⋅Sullivan, Ryan J⋅Sullivan, Ryan J⋅Sullivan, Ryan J⋅Sosman, Jeffrey A⋅Sosman, Jeffrey A⋅Sosman, Jeffrey A⋅Slingluff, Craig L⋅Slingluff, Craig L⋅Slingluff, Craig L⋅Lawrence, Donald P⋅Lawrence, Donald P⋅Lawrence, Donald P⋅Logan, Theodore F⋅Logan, Theodore F⋅Logan, Theodore F⋅Schuchter, Lynn M⋅Schuchter, Lynn M⋅Schuchter, Lynn M⋅Nair, Suresh⋅Nair, Suresh⋅Nair, Suresh⋅Fecher, Leslie⋅Fecher, Leslie⋅Fecher, Leslie⋅Buchbinder, Elizabeth I⋅Buchbinder, Elizabeth I⋅Buchbinder, Elizabeth I⋅Berghorn, Elmer⋅Berghorn, Elmer⋅Berghorn, Elmer⋅Ruisi, Mary⋅Ruisi, Mary⋅Ruisi, Mary⋅Kong, George⋅Kong, George⋅Kong, George⋅Jiang, Joel⋅Jiang, Joel⋅Jiang, Joel⋅Horak, Christine⋅Horak, Christine⋅Horak, Christine⋅Hodi, F Stephen⋅Hodi, F S and Hodi, F SThe Lancet. Oncology, vol. 17, (no. 7), pp. 943-955, July 2016.
| Journal Article
